REFRACTORY OVARIAN CARCINOMA TREATED WITH VINDESINE, ACLARUBICIN AND MITOMYCIN (VAM)

VernacularTitle:耐铂卵巢上皮癌VAM联合化疗近期疗效观察
Author: Jie TANG ; Shumo CAI ; Jianxuan FAN
Publication Type:Journal Article
From: Tumor 2001;(1):51-53
CountryChina
Language:Chinese
Abstract: Objective　To study the response rate and toxic side effect of Vindesine, aclarubicin and mitomycin (VAM) as a new regime of second line chemotherapy for ovarian carcinoma refractory to platinum group of drugs.Methods　From June 1997 through August 1998, 25 cases of refractory ovarian carcinoma were treated with VAM regime. The response rate and the side reactions were analyzed. Results　The overall response rate was 32.0%, with 3 complete response (CR) and 5 partial response (PR). In the platinum refractory, platinum-resistant platinum-senstitive strata, the response rates were 18.2% 28.6% and 57.1% respectively. Myelosuppression was the main toxic effect. Grade 3 and grade 4 neutropenia occurred in 40.0% and thrombocytopenia in 28.0% of the patients. Alopecia occurred in 32% of cases. Gastrointastinal, cardiac and neurologic toxicities were mild. Conclusion　VAM regime is a practical and effective second-line chemotherapy for patients with ovarian carcinoma refractory to platinum based chemothrapy.